Efficacy and safety of a new intravenous immunoglobulin (Panzyga®) in chronic immune thrombocytopenia

Abstract

Objectives: To assess the efficacy and safety of intravenous immunoglobulin (IVIG) 10% (Panzyga®), a novel human normal IVIG 10%, in patients with chronic immune thrombocytopenia (ITP). Background: First-line treatment options in ITP include IVIGs. Methods: In this prospective, open-label, non-controlled, multicentre, phase III study, patients received a daily dose of IVIG 10% (1 g kg−1 body weight) for two consecutive days. The primary end point was clinical response rate; secondary end points included alternate response definitions, time to response, response duration, platelet counts, regression of bleeding and safety. Results: Forty patients were enrolled (57·5% male, mean age 36·7 years); the full analysis set comprised 36 patients. A clinical response was seen for 29 of 36 patients (80·6%). Median time to response and response duration was 2 days and 14 days, respectively. IVIG 10% was well tolerated at a maximum infusion rate of 8 mg (kg min)−1 in all but one patient; adverse events were mainly mild to moderate in severity, and the most frequent was headache (42·5%). Conclusion: IVIG 10% is well tolerated even at a high infusion speed and induces a rapid platelet count increase, thus decreasing the bleeding rate and the severity of bleeding events. Trial registry: ClinicalTrials.gov record: NCT01349790.